UroGen Pharma Ltd (URGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.28B
Last updated: Nov 17, 2026 at 11:05 AM ET
UroGen Pharma Ltd (URGN) Earnings: Report Dates and Results
UroGen Pharma (URGN) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, UroGen Pharma reported EPS of -$0.03, below the $0.05 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
URGN has an expected report date of Mar 1, 2027.
URGN Earnings Call
The latest URGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, URGN beat 14, missed 23 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $89.00M, up 223.9% from $27.48M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.03 | $0.05 | -$0.07 - $0.19 | -160.00% | Miss | N/A | 6 | 5 up, 0 down | Nov 4, 2026 | $89.00M |
| Jun 30, 2026 | -$0.28 | -$0.38 | -$0.61 - -$0.16 | +26.32% | Beat | N/A | 8 | 5 up, 0 down | Aug 5, 2026 | $72.46M |
| Mar 31, 2026 | -$0.47 | -$0.48 | -$0.62 - -$0.11 | +2.08% | Beat | N/A | 8 | 2 up, 0 down | May 6, 2026 | $50.96M |
| Dec 31, 2025 | -$0.53 | -$0.48 | -$0.74 - -$0.31 | -9.94% | Miss | N/A | 7 | 0 up, 1 down | Mar 2, 2026 | $37.84M |
| Sep 30, 2025 | -$0.69 | -$0.68 | -$0.79 - -$0.52 | -1.47% | Miss | N/A | 7 | 0 up, 4 down | Nov 6, 2025 | $27.48M |
| Jun 30, 2025 | -$1.05 | -$0.82 | -$0.94 - -$0.60 | -28.05% | Miss | N/A | 7 | 1 up, 3 down | Aug 7, 2025 | $24.21M |
| Mar 31, 2025 | -$0.92 | -$0.79 | -$0.96 - -$0.37 | -16.46% | Miss | N/A | 6 | 1 up, 2 down | May 12, 2025 | $20.25M |
| Dec 31, 2024 | -$0.80 | -$0.72 | -$0.97 - -$0.55 | -11.11% | Miss | N/A | 7 | 0 up, 1 down | Mar 10, 2025 | $24.57M |
| Sep 30, 2024 | -$0.55 | -$0.82 | -$0.91 - -$0.76 | +32.93% | Beat | N/A | 7 | 0 up, 0 down | Nov 6, 2024 | $25.20M |
| Jun 30, 2024 | -$0.91 | -$0.83 | -$0.90 - -$0.77 | -9.64% | Miss | N/A | 5 | 1 up, 0 down | Aug 13, 2024 | $21.85M |
| Mar 31, 2024 | -$0.97 | -$0.87 | -$0.99 - -$0.75 | -11.49% | Miss | N/A | 5 | 1 up, 0 down | May 13, 2024 | $18.78M |
| Dec 31, 2023 | -$0.72 | -$0.68 | -$0.74 - -$0.61 | -5.88% | Miss | N/A | 5 | 0 up, 0 down | Mar 14, 2024 | $23.53M |
| Sep 30, 2023 | -$0.68 | -$0.87 | -$0.96 - -$0.73 | +21.84% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2023 | $20.85M |
| Jun 30, 2023 | -$1.03 | -$1.14 | -$1.18 - -$1.11 | +9.65% | Beat | N/A | 5 | 0 up, 1 down | Aug 10, 2023 | $21.14M |
| Mar 31, 2023 | -$1.30 | -$1.24 | -$1.77 - -$1.21 | -4.84% | Miss | N/A | 6 | 0 up, 0 down | May 11, 2023 | $17.19M |
| Dec 31, 2022 | -$1.22 | -$1.07 | -$1.42 - -$0.89 | -14.02% | Miss | N/A | 6 | 0 up, 0 down | Mar 16, 2023 | $18.09M |
| Sep 30, 2022 | -$1.13 | -$1.14 | -$1.69 - -$1.03 | +0.88% | Beat | N/A | 6 | 0 up, 0 down | Nov 10, 2022 | $16.10M |
| Jun 30, 2022 | -$1.18 | -$1.33 | N/A | +11.28% | Beat | N/A | N/A | 1 up, 0 down | Aug 11, 2022 | $16.60M |
| Mar 31, 2022 | -$1.25 | -$1.25 | -$1.58 - -$1.18 | 0.00% | In line | N/A | 6 | 0 up, 0 down | May 10, 2022 | $13.56M |
| Dec 31, 2021 | -$1.27 | -$1.17 | -$1.39 - -$1.05 | -8.55% | Miss | N/A | 6 | 0 up, 0 down | Mar 21, 2022 | $16.17M |
| Sep 30, 2021 | -$1.35 | -$1.33 | -$1.42 - -$1.10 | -1.50% | Miss | N/A | 6 | N/A | Nov 15, 2021 | $11.35M |
| Jun 30, 2021 | -$1.17 | -$1.09 | -$1.32 - -$0.95 | -7.34% | Miss | N/A | 5 | N/A | Aug 4, 2021 | $13.03M |
| Mar 31, 2021 | -$1.17 | -$1.25 | -$1.49 - -$0.84 | +6.40% | Beat | N/A | 8 | N/A | May 13, 2021 | $7.49M |
| Dec 31, 2020 | -$1.38 | -$1.37 | -$1.84 - -$1.19 | -0.73% | Miss | N/A | 8 | N/A | Mar 18, 2021 | $7.97M |
| Sep 30, 2020 | -$1.31 | -$1.47 | -$1.59 - -$1.38 | +10.88% | Beat | N/A | 8 | N/A | Nov 9, 2020 | $3.46M |
| Jun 30, 2020 | -$1.44 | -$1.52 | -$1.75 - -$1.08 | +5.26% | Beat | N/A | 9 | N/A | Aug 10, 2020 | $372000 |
| Mar 31, 2020 | -$1.79 | -$1.62 | -$1.90 - -$1.40 | -10.49% | Miss | N/A | 9 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$1.86 | -$1.70 | -$1.85 - -$1.55 | -9.41% | Miss | N/A | 9 | N/A | Mar 2, 2020 | N/A |
| Sep 30, 2019 | -$1.06 | -$1.28 | -$1.42 - -$1.17 | +17.19% | Beat | N/A | 8 | N/A | Nov 12, 2019 | N/A |
| Jun 30, 2019 | -$1.08 | -$1.20 | -$1.33 - -$1.11 | +10.00% | Beat | N/A | 9 | N/A | Aug 9, 2019 | $18000 |
| Mar 31, 2019 | -$1.11 | -$1.26 | -$1.31 - -$0.59 | +11.90% | Beat | N/A | 7 | N/A | May 9, 2019 | N/A |
| Dec 31, 2018 | -$1.46 | -$1.24 | -$1.46 - -$0.92 | -17.74% | Miss | N/A | 7 | N/A | Feb 28, 2019 | $845000 |
| Sep 30, 2018 | -$1.28 | -$1.11 | -$1.14 - -$0.92 | -15.32% | Miss | N/A | 6 | N/A | Nov 12, 2018 | $283000 |
| Jun 30, 2018 | -$1.14 | -$0.93 | -$1.00 - -$0.80 | -22.58% | Miss | N/A | 5 | N/A | Aug 14, 2018 | $364000 |
| Mar 31, 2018 | -$0.88 | -$0.72 | -$0.84 - -$0.63 | -22.22% | Miss | N/A | 5 | N/A | May 15, 2018 | $481000 |
| Dec 31, 2017 | -$0.74 | -$0.64 | -$0.69 - -$0.41 | -15.63% | Miss | N/A | 5 | N/A | Mar 15, 2018 | $327000 |
| Sep 30, 2017 | -$0.02 | $0.11 | N/A | -118.18% | Miss | N/A | N/A | N/A | Nov 14, 2017 | $7.81M |
| Jun 30, 2017 | -$0.68 | -$1.77 | N/A | +61.58% | Beat | N/A | N/A | N/A | Aug 14, 2017 | $7.81M |
| Mar 31, 2017 | -$1.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 5, 2017 | $19000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.19, after -$3.23 the year before. It was -$2.55 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.19 | N/A |
| Dec 31, 2024 | -$3.23 | N/A |
| Dec 31, 2023 | -$3.73 | N/A |
| Dec 31, 2022 | -$4.78 | N/A |
| Dec 31, 2021 | -$4.96 | N/A |
| Dec 31, 2020 | -$5.92 | N/A |
| Dec 31, 2019 | -$5.11 | N/A |
| Dec 31, 2018 | -$4.76 | N/A |
| Dec 31, 2017 | -$2.55 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,038 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,437 | 13 | |
| 2026Q1 | Mar 31, 2026 | 5,500 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,392 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,200 | 13 | |
| 2025Q2 | Jun 30, 2025 | 6,317 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,808 | 13 | |
| 2024Q4 | Dec 31, 2024 | 6,429 | 12 |
2026Q3 Earnings Call
Opening remarks
Vincent I. Perrone Senior Director of Investor Relations Thank you. Good morning, everyone, and welcome to UroGen Pharma's Third Quarter 2026 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30, 2026. The release can be accessed on the Investors portion of our website at investors.urogen.com. Joining me today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; and Christopher Degnan, Chief Financial Officer. On today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to ZUSDURI and Jelmyto; our ongoing and planned clinical trials and nonclinical studies; commercial and clinical development milestones; market and revenue opportunities; our commercialization strategy and expectations; anticipated data, regulatory filings and decisions; the importance of ZUSDURI's growth for UroGen's long-term strategy; anticipated benefits of our strategic collaboration with IntraGel Therapeutics; the potential benefits of our products and product candidates; future R&D efforts and milestones; our corporate goals; and 2026 financial guidance, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements. I will now turn the call over to Liz Barrett, Chief Executive Officer. Liz?
Elizabeth A. Barrett Chief Executive Officer Good morning, and thank you for joining us today. We delivered another quarter of strong execution, with ZUSDURI generating $68 million in net product revenue, representing 35% sequential quarter-over-quarter growth. More importantly, the underlying commercial trends continue to strengthen, with increasing repeat utilization, broader physician adoption, and continued expansion into community practices. Together, these trends reinforce our confidence that ZUSDURI is scaling successfully and establishing a strong foundation for sustained growth. This momentum reflects the product's differentiated value proposition. As the first and only FDA-approved medicine for adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer, ZUSDURI offers a primary surgery-free alternative for a disease that historically has been managed through repetitive surgical interventions. We believe this differentiated approach provides patients an opportunity to have more recurrence-free and treatment-free living, and is increasingly changing how physicians think about treating these patients. Turning to the operating metrics, as of September 30, 2026, we had over 1,500 activated accounts. With a substantial foundation of activated accounts now in place, our commercial team's focus is shifting toward driving utilization within these practices, converting new prescribers into repeat users, and expanding adoption across the broader physician community.
Frequently Asked Questions About URGN
When is UroGen Pharma's next earnings date?
UroGen Pharma's next earnings report is expected for Mar 1, 2027.
Did URGN beat earnings estimates last quarter?
No. UroGen Pharma reported EPS of -$0.03 for the quarter ended Sep 30, 2026, below the $0.05 estimate by 160.00%.
What EPS do analysts expect from URGN next quarter?
The consensus EPS estimate for UroGen Pharma for the quarter ending Dec 31, 2026 is $0.46 from 9 analysts, with estimates from $0.13 to $0.69.
How often does URGN beat earnings estimates?
UroGen Pharma beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -24.83%.
URGN pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts